Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway

Lu, Mengchen, Liu, Tian, Jiao, Qiong, Ji, Jianai, Tao, Mengmin, Liu, Yijun, You, Qidong, Jiang, Zhengyu·2018·European Journal of Medicinal Chemistry
DOI 10.1016/j.ejmech.2018.01.063

Cited by (321)

Items 101–200 of 321

  1. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
    Yuqing Lu, Yuewen Yang, Guanghao Zhu, Hairong Zeng, Yi‐Ming Fan, Fujia Guo, Dongshu Xu, Boya Wang, Dapeng Chen, Guang‐Bo Ge · 2023 · International Journal of Biological Sciences
  2. Advances in developing noncovalent small molecules targeting Keap1
    Marilia Barreca, Yuting Qin, Marie Elodie Hélène Cadot, Paola Barraja, Anders Bach · 2023 · Drug Discovery Today
  3. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
    Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid · 2023 · European Journal of Medicinal Chemistry
  4. Recent advances in targeted protein degraders as potential therapeutic agents
    Na Yang, Bo Kong, Zhaohong Zhu, Fei Huang, Liliang Zhang, Tao Lu, Yadong Chen, Yanmin Zhang, Yulei Jiang · 2023 · Molecular Diversity
  5. Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly
    Erin E. Congdon, Yixiang Jiang, Einar M. Sigurdsson · 2021 · Seminars in Cell and Developmental Biology
  6. Exploration of Aberrant E3 Ligases Implicated in Alzheimer’s Disease and Development of Chemical Tools to Modulate Their Function
    Frances Potjewyd, Alison D. Axtman · 2021 · Frontiers in Cellular Neuroscience
  7. Chemical Protein Degradation Approach and its Application to Epigenetic Targets
    Yukihiro Itoh · 2018 · The Chemical Record
  8. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
    María Maneiro, Elena De Vita, Daniel Conole, Cyrille S. Kounde, Qisi Zhang, Edward W. Tate · 2021 · Progress in medicinal chemistry
  9. Is PROTAC technology really a game changer for central nervous system drug discovery?
    Kayla Farrell, Timothy J. Jarome · 2021 · Expert Opinion on Drug Discovery
  10. New therapies on the horizon: Targeted protein degradation in neuroscience
    James A Gregory, Christopher M. Hickey, Juan D. Chavez, Angela M. Cacace · 2024 · Cell chemical biology
  11. Covalent Proximity Inducers
    Nir London · 2024 · Chemical Reviews
  12. Peptides for disrupting and degrading amyloids
    Chu-Qiao Liang, Yanmei Li · 2021 · Current Opinion in Chemical Biology
  13. Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives
    Jiao Li, Zhenyu Cai, Xu‐Wen Li, Chunlin Zhuang · 2022 · Journal of Medicinal Chemistry
  14. Applications of protein ubiquitylation and deubiquitylation in drug discovery
    Yilin Chen, Haoan Xue, Jianping Jin · 2024 · Journal of Biological Chemistry
  15. A comprehensive review of BET-targeting PROTACs for cancer therapy
    Xiaoli Zhou, Fang Zhao, Yong-Tao Xu, Yuanyuan Guan, Tong Yu, Yizhe Zhang, Ying‐Chao Duan, Yuan Zhao · 2022 · Bioorganic & Medicinal Chemistry
  16. Research progress of PROTACs for neurodegenerative diseases therapy
    Zhifang Cai, Zunhua Yang, Huilan Li, Yuanying Fang · 2024 · Bioorganic Chemistry
  17. Tau Clearance Mechanisms
    Maoping Tang, Jarreau Harrison, Carol A. Deaton, Gail V.W. Johnson · 2019 · Advances in experimental medicine and biology
  18. Pharmacological Modulators of Tau Aggregation and Spreading
    Antonio Dominguez‐Meijide, Eftychia Vasili, Tiago F. Outeiro · 2020 · Brain Sciences
  19. Tau protein aggregation: Key features to improve drug discovery screening
    Johanna Giovannini, Willy Smeralda, Marie Jouanne, Jana Sopková‐de Oliveira Santos, Marco Catto, Anne Sophie Voisin‐Chiret · 2022 · Drug Discovery Today
  20. Peptide-Based PROTAC: The Predator of Pathological Proteins
    Au, Yan Zi, Wang, Tingjian, Sigua, Logan H., Qi, Jun · 2020 · Cell Chemical Biology
  21. PROTACs technology for targeting non-oncoproteins: Advances and perspectives
    Chao Wang, Yujing Zhang, Dongming Xing, Renshuai Zhang · 2021 · Bioorganic Chemistry
  22. Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases
    Bo Ram Han, Mengfei Wang, Jiayi Li, Qiushi Chen, Niubing Sun, Xuezhi Yang, Qingwei Zhang · 2023 · European Journal of Medicinal Chemistry
  23. Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
    Lisha Ou, Mekedlawit T. Setegne, Jeandele Elliot, Fangfang Shen, Laura M. K. Dassama · 2025 · Chemical Reviews
  24. Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer’s disease and related tauopathies
    Jingfen Su, Yue Xiao, Linyu Wei, Huiyang Lei, Fei Sun, Weixia Wang, Jun Yin, Rui Xiong, Shihong Li, Pei Zhang et al. · 2024 · 中国科学通报：英文版
  25. Unleashing the Power of Covalent Drugs for Protein Degradation
    Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, Liang Shen, Hong‐Min Liu, Ying Liu, Yi‐Chao Zheng, Xing‐Jie Dai · 2025 · Medicinal Research Reviews
  26. Specific Degradation of Endogenous Tau Protein and Inhibition of Tau Fibrillation by Tanshinone IIA through the Ubiquitin–Proteasome Pathway
    Nan Cai, Jiajie Chen, Decheng Bi, Liang Gu, Lijun Yao, Xiuting Li, Hui Li, Hong Yuan Xu, Zhangli Hu, Qiong Liu et al. · 2020 · Journal of Agricultural and Food Chemistry
  27. Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization
    Yuanyuan Shan, Ru Si, Jin Wang, Qingqing Zhang, Jing Li, Yuexiang Ma, Jie Zhang · 2020 · European Journal of Medicinal Chemistry
  28. High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
    Kristin M. Riching, Sarah D. Mahan, Marjeta Urh, Danette L. Daniels · 2020 · Journal of Visualized Experiments
  29. Health position paper and redox perspectives – Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases
    Cuadrado, Antonio, Cazalla, Eduardo, Bach, Anders, Bathish, Boushra, Naidu, Sharadha Dayalan, DeNicola, Gina M., Dinkova-Kostova, Albena T., Fernández-Ginés, Raquel, Grochot-Przeczek, Anna, Hayes, John D. et al. · 2025 · Redox Biology
  30. The new direction of drug development: Degradation of undruggable targets through targeting chimera technology
    Xuewu Liang, Hairu Ren, Fengyang Han, Renwen Liang, Jiayan Zhao, Hong Liu · 2023 · Medicinal Research Reviews
  31. Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing pathways in neurodegenerative disorders and cancer
    Aastha Kaushik, Somya Parashar, Rashmi K. Ambasta, Pravir Kumar · 2024 · Ageing Research Reviews
  32. Systemic Administration of Neurotransmitter‐Derived Lipidoids‐PROTACs‐DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy
    Baofeng Gong, Weicong Zhang, Wei Cong, Yuankai Gu, Wenbo Ji, Tong Yin, Honglei Zhou, Honggang Hu, Jianhua Zhuang, Yi Luo et al. · 2024 · Advanced Healthcare Materials
  33. Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions
    Akash Vikal, Rashmi Maurya, Brij Bihari Patel, Rajeev Kr. Sharma, Preeti Patel, Umesh Kumar Patil, Balak Das Kurmi · 2024 · Drug Delivery and Translational Research
  34. The application of ubiquitin ligases in the PROTAC drug design
    Yilin Chen, Jianping Jin · 2020 · Acta Biochimica et Biophysica Sinica
  35. Central Nervous System Targeted Protein Degraders
    Bedwyr ab Ion Thomas, H. Lois Lewis, Dyfyr Heulyn Jones, Simon E. Ward · 2023 · Biomolecules
  36. PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
    Narayanaperumal Pravin, Krzysztof Jóźwiak · 2024 · European Journal of Medicinal Chemistry
  37. Emerging modes-of-action in drug discovery
    Eric Valeur, Frank Narjes, Christian Ottmann, Alleyn T. Plowright · 2019 · MedChemComm
  38. Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
    Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, Wendy Xolalpa, Allan Michael Jordan, Roland Hjerpe, Manuel S. Rodríguez · 2024 · Cells
  39. Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
    Sandra Kuemper, Andrew G. Cairns, Kristian Birchall, Zhi Yao, Jonathan M. Large · 2024 · Frontiers in Molecular Neuroscience
  40. Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress
    Jing Chen, Disheng Feng, Rui Zhu, Hua Li, Lixia Chen · 2025 · Redox Biology
  41. Peptide-based PROTACs: Current Challenges and Future Perspectives
    Huidan Wang, Miao Chen, Xiaoyuan Zhang, Songbo Xie, Jie Qin, Jingrui Li · 2023 · Current Medicinal Chemistry
  42. Bivalent inhibitors of the BTB E3 ligase KEAP1 enable instant NRF2 activation to suppress acute inflammatory response
    Mengchen Lu, Jianai Ji, Yifei Lv, Jing Zhao, Yuting Liu, Qiong Jiao, Tian Liu, Yi Mou, Qidong You, Zhengyu Jiang · 2023 · Cell chemical biology
  43. Recent advances in developing targeted protein degraders
    Binbin Cheng, Hongqiao Li, Xiaopeng Peng, Jianjun Chen, Chuxiao Shao, Zhihua Kong · 2024 · European Journal of Medicinal Chemistry
  44. Workflow for E3 Ligase Ligand Validation for PROTAC Development
    Nebojša Miletić, Janik Weckesser, Thorsten Mosler, Rajeshwari Rathore, Marina E. Hoffmann, Paul Gehrtz, Sarah Schlesiger, Ingo Volker Hartung, Nicola Berner, Stephanie Wilhelm et al. · 2025 · ACS Chemical Biology
  45. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy–Lysosome Pathway
    Katelyn B. Cassidy, Heng Zhao · 2021 · Biochemistry
  46. Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review
    Mary Sravani Galla, Nitika Sharma, Priyanka Mishra, Nagula Shankaraiah · 2024 · RSC Medicinal Chemistry
  47. Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
    Anastasia A. Sachkova, Daria V. Andreeva, Alexander S. Tikhomirov, Alexander Mikhailovich Scherbakov, Diana I. Salnikova, Danila Vladimirovich Sorokin, Fedor B. Bogdanov, Yulia D. Rysina, Andrey Egorovich Shchekotikhin, Ekaterina S. Shchegravina et al. · 2022 · Pharmaceutics
  48. Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation
    Shareef Shaik, Prasanna Kumar Reddy Gayam, Manish Chaudhary, Gurvinder Singh, Aravinda Pai · 2024 · Bioorganic Chemistry
  49. Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system
    Ke Ma, Xiao-Xiao Han, Xiaoxiao Han, Songlin Zhou · 2021 · Neural Regeneration Research
  50. Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease
    Bhatia, Shiveena, Singh, Manjinder, Singh, Tanveer, Singh, Varinder · 2023 · Neurochemical Research
  51. A tau dephosphorylation-targeting chimera selectively recruits protein phosphatase-1 to ameliorate Alzheimer’s disease and tauopathies
    Yue Xiao, Linyu Wei, Jingfen Su, Huiyang Lei, Fei Sun, Mengzhu Li, Shihong Li, Xiaochuan Wang, Jie Zheng, Jian–Zhi Wang · 2024 · Cell chemical biology
  52. The Peptide PROTAC Modality: A New Strategy for Drug Discovery
    Youmin Zhu, Yu Dai, Yuncai Tian · 2025 · MedComm
  53. Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases
    Gouri Chopra, Shabnam Shabir, Sumaira Yousuf, Simran Kauts, Shahnawaz Ali Bhat, Ashiq Hussain Mir, Mahendra P. Singh · 2022 · Molecular Neurobiology
  54. Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation
    Jin‐Jiao Chen, Jin‐Mei Jin, Wenjie Gu, Zeng Zhao, Yuan Hu, Yudong Zhou, Dale G. Nagle, Qiulei Xi, Xuemei Zhang, Qingyan Sun et al. · 2023 · Cancer Science
  55. Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein
    Norihito Shibata, Nobumichi Ohoka, Takayuki Hattori, Mikihiko Naito · 2019 · Chemical and Pharmaceutical Bulletin
  56. Computational strategies for PROTAC drug discovery
    Jia Wu, Wanhe Wang, Chung‐Hang Leung · 2023 · Acta Materia Medica
  57. Tau protein plays a role in the mechanism of cognitive disorders induced by anesthetic drugs
    Zheping Chen, Shenghan Wang, Zhaoqian Meng, Yuyang Ye, Guoliang Shan, Xinyue Wang, Xin Zhao, Yanwu Jin · 2023 · Frontiers in Neuroscience
  58. Targeted protein degradation for the treatment of Parkinson’s disease: Advances and future perspective
    Roshanak Amirian, Mehdi Azadi Badrbani, Hossein Derakhshankhah, Zhila Izadi, Mohammad‐Ali Shahbazi · 2023 · Biomedicine & Pharmacotherapy
  59. Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
    Yerim Jin, Yeongju Lee · 2024 · ChemMedChem
  60. Targeted protein degradation: expanding the technology to facilitate the clearance of neurotoxic proteins in neurodegenerative diseases
    Xin Wang, Wen Shuai, Panpan Yang, Yinyang Liu, Yiwen Zhang, Guan Wang · 2024 · Ageing Research Reviews
  61. Targeted protein modification as a paradigm shift in drug discovery
    Amirian, Roshanak, Azadi Badrbani, Mehdi, Izadi, Zhila, Samadian, Hadi, Bahrami, Gholamreza, Sarvari, Sajad, Abdolmaleki, Sara, Nabavi, Seyed Mohammad, Derakhshankhah, Hossein, Jaymand, Mehdi · 2023 · European Journal of Medicinal Chemistry
  62. Dementia Therapy Targeting Tau
    Luc Buée · 2019 · Advances in experimental medicine and biology
  63. Huntingtin Ubiquitination Mechanisms and Novel Possible Therapies to Decrease the Toxic Effects of Mutated Huntingtin
    Annarita Fiorillo, Veronica Morea, Gianni Colotti, Andrea Ilari · 2021 · Journal of Personalized Medicine
  64. Involvement of heterologous ubiquitination including linear ubiquitination in Alzheimer’s disease and amyotrophic lateral sclerosis
    Yusuke Sato, Seigo Terawaki, Daisuke Oikawa, Kouhei Shimizu, Yoshinori Okina, Hidefumi Ito, Fuminori Tokunaga · 2023 · Frontiers in Molecular Biosciences
  65. Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer’s disease
    Meihao Liang, Lili Gu, Hongjie Zhang, Jingli Min, Zunyuan Wang, Zhen Ma, Chixiao Zhang, Shenxin Zeng, Youlu Pan, Dongmei Yan et al. · 2022 · ACS Omega
  66. 24-Hydroxycholesterol Induces Tau Proteasome-Dependent Degradation via the SIRT1/PGC1α/Nrf2 Pathway: A Potential Mechanism to Counteract Alzheimer’s Disease
    Gabriella Testa, Serena Giannelli, Barbara Sottero, Erica Staurenghi, Giorgio Giaccone, Paola Caroppo, Paola Gamba, Gabriella Leonarduzzi · 2023 · Antioxidants
  67. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
    Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Bowen Li, Mei Yang, Edouard Collins Nice, Huili Zhu, Canhua Huang · 2023 · European Journal of Medicinal Chemistry
  68. Recent advances of PROTACs technology in neurodegenerative diseases
    Chao Wang, Yujing Zhang, Shanbo Yang, Dongming Xing · 2023 · Arabian Journal of Chemistry
  69. T217-Phosphorylation Exacerbates Tau Pathologies and Tau-Induced Cognitive Impairment
    Xin Wang, Qian Rong Liu, Xiaoguang Li, Qiuzhi Zhou, Dongqin Wu, Shihong Li, Yanchao Liu, Jian‐Zhi Wang · 2021 · Journal of Alzheimer s Disease
  70. The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease
    Suresh Kumar, Michael R. Mattern, Matthew S. Goldberg, Tauseef R. Butt · 2023 · NeuroMolecular Medicine
  71. New PROTAC Designs for Targeted Protein Degradation in 2021–2025: Novel E3 Ligases and Pre-PROTACs
    Wei Peng, Xiaoyan Pan, Shiqun Wang, G. Huang, Yu Qian · 2026 · Journal of Medicinal Chemistry
  72. Effect of Modification Strategies on the Biological Activity of Peptides/Proteins
    Jian Ma, Yan Liang, Jingkui Yang, Yujian He, Li Wu · 2023 · ChemBioChem
  73. Targeted degradation of α-synuclein by arginine-based PROTACs
    Linjing Shen, Jianchao Zhang, Zhaoran Wang, Yaxuan Liu, Shengjin Cui, Hai Rao · 2025 · Journal of Biological Chemistry
  74. The Involvement of Post-Translational Modifications in Regulating the Development and Progression of Alzheimer’s Disease
    Pei-Pei Guan, Pu Wang · 2023 · Molecular Neurobiology
  75. Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives
    Yangguo Zhou, Qiong Zhang, Ziquan Zhao, Xiuqi Hu, Qidong You, Zhengyu Jiang · 2024 · European Journal of Medicinal Chemistry
  76. Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1
    Dan Luo, Rong‐Hua Luo, Weilin Wang, Rui Deng, Shirui Wang, Xinyu Ma, Chunlan Pu, Yuanyuan Liu, Hongjia Zhang, Su Yu et al. · 2024 · Bioorganic & Medicinal Chemistry Letters
  77. Proteolysis-targeting Chimeras for Targeting Protein for Degradation
    Jianguo Qi, Gang Zhang · 2019 · Future Medicinal Chemistry
  78. Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
    Qiuzhi Zhou, Weixia Wang, Chunchu Deng · 2025 · Molecular Neurobiology
  79. PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras
    Ritesh P. Bhole, Sapana Patil, Harshad S. Kapare, Rupesh V. Chikhale, Shailendra Shivaji Gurav · 2024 · Current Topics in Medicinal Chemistry
  80. Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis
    Shang Li, Liangliang Ma, Xinxin Li, Yuhan Jiang, Zhongwen Luo, Fucheng Yin, Yonglei Zhang, Yifan Chen, Siyuan Wan, Han Zhou et al. · 2024 · Journal of Medicinal Chemistry
  81. Proteolysis-targeting influenza vaccine strains induce broad-spectrum immunity and in vivo protection
    Jinying Shen, Jing Li, Quan Shen, Jihuan Hou, Chunhe Zhang, Haiqing Bai, Xiaoni Ai, Yinlei Su, Zihao Wang, Yunfei Zhang et al. · 2025 · Nature Microbiology
  82. Conquering PROTAC molecular design and drugability
    Ritesh P. Bhole, Sonali Labhade, Shailendra Shivaji Gurav · 2025 · Bioanalysis
  83. Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules
    Alexandré Delport, Raymond Hewer · 2019 · Molecules
  84. Chimera induced protein degradation: PROTACs and beyond
    Lina Yin, Qingzhong Hu · 2020 · European Journal of Medicinal Chemistry
  85. Contemporary trends in targeted protein degradation for neurodegenerative diseases
    Gulshan Kumar, Vaibhav Thakur, Satish Sardana, Vinod K. Tiwari, Dilip Sharma, Asim Kumar · 2025 · European Journal of Medicinal Chemistry
  86. Programmable PROTAC delivery for precise and spatiotemporal protein degradation
    Jinhan Sheng, Tianyu Ma, Yu Wu, Ming Wang · 2026 · Chemical Communications
  87. Amino acid-based biomaterials for modulation of cell behaviors: from mechanisms to biomedical applications
    Mingyue Liu, Jinjin Chen, Hongjie Li, Yulong Ma, Qingyang Xiao, Jianxun Ding, Jinghong Li, Xuesi Chen · 2026 · Chemical Society Reviews
  88. Kelch-like proteins in the gastrointestinal tumors
    Anbo Fu, Senfeng Xiang, Qiaojun He, Meidan Ying · 2022 · Acta Pharmacologica Sinica
  89. Upregulation of the ESCRT pathway and multivesicular bodies accelerates degradation of proteins associated with neurodegeneration
    Ron Benyair, Sai Srinivas Panapakkam Giridharan, Pilar Rivero-Ríos, Junya Hasegawa, Emily Bristow, Eeva‐Liisa Eskelinen, Merav D. Shmueli, Vered Fishbain-Yoskovitz, Yifat Merbl, Lisa M. Sharkey et al. · 2023 · Autophagy Reports
  90. Development of natural product-based targeted protein degraders as anticancer agents
    Cheng Chen, Yanyan Feng, Chen Zhou, Zhouyan Liu, Ziwei Tang, Ye Zhang, Tong Li, Chenglei Gu, Jichao Chen · 2024 · Bioorganic Chemistry
  91. Targeted protein degradation with bifunctional molecules as a novel therapeutic modality for Alzheimer's disease & beyond
    Carl Alexander Sandhof, Heide F.B. Murray, M. Catarina Silva, Stephen J. Haggarty · 2024 · Neurotherapeutics
  92. Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies
    Elisa Uliassi, María Laura Bolognesi, Andrea Milelli · 2025 · ACS Pharmacology & Translational Science
  93. Advancements in PROTAC-based therapies for neurodegenerative diseases
    Deyuan Kong, Liying Meng, Pengfei Lin, Guanzhao Wu · 2025 · Future Medicinal Chemistry
  94. Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease
    Stacie C. Weninger, Bjørn Sperling, Robert Alexander, Magnus Ivarsson, Fiona M. Menzies, Peter Powchik, Christopher J. Weber, C. Anthony Altar, Ronald G. Crystal, Stephen J. Haggarty et al. · 2020 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  95. Targeted protein degradation might present a novel therapeutic approach in the fight against African trypanosomiasis
    Ammar Usman Danazumi, Ibtida Tabassum Ishmam, Salisu Idris, Matylda Anna Izert, E.O. Balogun, Maria W. Górna · 2023 · European Journal of Pharmaceutical Sciences
  96. Targeting neurodegenerative disease-associated protein aggregation with proximity-inducing modalities
    Ruixin Ge, Miao Chen, Qingchao Li, Min Liu, Jun Zhou, Songbo Xie · 2025 · Acta Pharmacologica Sinica
  97. PROTAC: A Novel Technology for Drug Development**
    Jie Li, Jie‐Qing Liu · 2020 · ChemistrySelect
  98. Advances in Peptide-Based Chimeric Strategies for Targeted Protein Degradation
    Yixuan Wang, Jingyuan Zhao, Hong Yuan, Shuai Li · 2025 · Journal of Medicinal Chemistry
  99. Emerging strategies for the genetic dissection of gene functions, cell types, and neural circuits in the mammalian brain
    Ling Gong, Xue Liu, Jinyun Wu, Miao He · 2021 · Molecular Psychiatry
  100. Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation
    Mai Kuriyama, Chu Fan Wang, Tatsuya Nagase, Youhei Sohma, Motomu Kanai, Yukiko Hori, Taisuke Tomita · 2025 · Neurotherapeutics